Drug Interactions between deuruxolitinib and rifampin
This report displays the potential drug interactions for the following 2 drugs:
- deuruxolitinib
- rifampin
Interactions between your drugs
rifAMPin deuruxolitinib
Applies to: rifampin and deuruxolitinib
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Concomitant use of deuruxolitinib with potent CYP450 3A4 and moderate or potent CYP450 2C9 inducers may significantly decrease the plasma concentrations and therapeutic efficacy of deuruxolitinib. According to the prescribing information, deuruxolitinib is primarily metabolized by CYP450 2C9 (76%) and to a lesser extent by CYP450 3A4 (21%) and 1A2 (3%). Concomitant use of a single dose of deuruxolitinib 12 mg (1.5 times the approved 8 mg dose) with multiple doses of the potent CYP450 3A4 and moderate 2C9 inducer rifampin (600 mg) decreased deuruxolitinib peak plasma concentration (Cmax) and systemic exposure (AUC) by 41% and 78%, respectively.
MANAGEMENT: Use of deuruxolitinib with dual potent CYP450 3A4 and moderate to potent CYP450 2C9 inducers should generally be avoided.
Drug and food/lifestyle interactions
rifAMPin food/lifestyle
Applies to: rifampin
Food can decrease the levels of rifAMPin in your body. Taking rifAMPin on an empty stomach (at least 30 minutes before or 2 hours after a meal) will make it easier for your body to absorb the medication. Avoid drinking alcohol while taking rifAMPin because alcohol use may increase the risk of damage to your liver. It is important to seek immediate medical care if you experience any severe side effects or symptoms of liver damage such as fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
deuruxolitinib food/lifestyle
Applies to: deuruxolitinib
Consumer information for this interaction is not currently available.
MONITOR: Smoking during treatment with deuruxolitinib may increase the risk of major adverse cardiovascular events (MACE) and the risk of developing malignancies. In clinical studies of deuruxolitinib, individuals who were current or former smokers had an additional increased risk of overall malignancies. Also, deuruxolitinib may increase patients' risk of MACE, including myocardial infarction, stroke, and cardiovascular death.
MANAGEMENT: Caution is advised if deuruxolitinib is prescribed to current or past smokers. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. The manufacturer recommends discontinuing deuruxolitinib in patients that have experienced a myocardial infarction or stroke. Deuruxolitinib may be taken with or without food.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Report options
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.